Source: Annual Congress 2010 - Biomarkers for lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Petrovic, N. Ilic, I. Cekerevac, L. Novkovic, V. Radulovic, V. Cupurdija (Kragujevac, Republic Of Serbia). Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis. Eur Respir J 2010; 36: Suppl. 54, 3246

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003 Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001 Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003 Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Elevated level of circulating matrix metalloproteinase-9 in non-small lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 229s Year: 2002 Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004 Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Serum hepcidin and iron are associated with non-small cell lung cancer stage Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer Source: Eur Respir J 2010; 36: 885-892 Year: 2010 Association between C-reactive protein and survival in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007 Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002 Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Prognostic value of neutrophil to lymphocyte ratio in patients with advanced non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018